4747 Executive Drive
3 articles with Artiva Biotherapeutics
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today U.S. Food and Drug Administration (FDA) allowance of the company’s investigational new drug (IND) application for AB-101, an optimized and cryopreserved off-the-shelf NK cell therapy.
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing allogeneic natural killer cell therapies, announced the launch of the company with the close of a $78 million Series A financing.